We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Because of changes to the tax code, many investors are hoping M&A activity will pick up. Others are just hoping they can get a handle on rising stocks. Here are three biopharma stocks worth keeping an eye on.